allergytalk

Welcome to Season Two of Allergytalk! In this season, we are going to introduce you to each of the Allergy Watch assistant editors who work so hard on scouring the literature in allergy and immunology and bring you the most interesting articles in every issue! Today we are again joined by Dr. Vivian Hernandez-Trujillo from Nicklaus Children's Hospital and will be reviewing the July-Aug 2022 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.  You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! Articles Reviewed: Initial presenting manifestations in 16,486 patients with inborn errors of immunity include infections and noninfectious manifestations. Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis. Importance of Supplemental Patch Testing Beyond a Screening Series for Patients With Dermatitis: The North American Contact Dermatitis Group Experience.   Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.   Today's speakers have the following disclosures: Dr. Lee has nothing to disclose Dr. Hernandez-Trujillo:  Speaker Takeda, CSL Advisory boards Takeda, Regeneron, Sanofi Consultant  Kaleo, Pharming, Enzyvant, National Peanut Board, Allergy and Asthma Network Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst

Welcome to Season Two of Allergytalk! In this season, we are going to introduce you to each of the Allergy Watch assistant editors who work so hard on scouring the literature in allergy and immunology and bring you the most interesting articles in every issue! Today we are again joined by Dr. Anthony Montanaro from Oregon Health & Science University and will be reviewing the Jan-Feb 2022 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.  You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! Articles Reviewed: Initial presenting manifestations in 16,486 patients with inborn errors of immunity include infections and noninfectious manifestations. Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis. Importance of Supplemental Patch Testing Beyond a Screening Series for Patients With Dermatitis: The North American Contact Dermatitis Group Experience.   Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.   Today's speakers have the following disclosures: Dr. Lee has nothing to disclose Dr. Montanaro has done research with AstraZeneca, Regeneron, Theravance, and Teva Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst, Novartis

Welcome to Season Two of Allergytalk! Starting with this episode, we are going to introduce you to each of the Allergy Watch assistant editors who work so hard on scouring the literature in allergy and immunology and bring you the most interesting articles in every issue! Today we are joined by Dr. Anthony Montanaro from Oregon Health & Science University and will be reviewing the Jan-Feb 2022 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.  You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! Articles Reviewed: Use of multiple epinephrine doses in anaphylaxis: A systematic review and meta-analysis. First-Dose mRNA COVID-19 Vaccine Allergic Reactions: Limited Role for Excipient Skin Testing. Differences in oral food challenge reaction severity based on increasing age in a pediatric population.   Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Episode 3: Severe pediatric asthma-beyond standard therapy, the role of current and future therapies including biologics Description: Though severe pediatric asthma only represents from 2 to 5% of the children suffering with this condition, it represents a major share of the cost, resource utilization, and morbidity. It is important that allergists have a good gasp of this condition and how it differs from the adult population. Topics include appropriate workup, comorbidities, steroid burden.   Learning Objectives: Be able to discuss the burden of severe pediatric asthma and issues in optimal medication adherence in this population Be able to evaluate the child with severe asthma and screen for corticosteroid overuse in and remedies to decrease it in this population Be able to interpret the mechanisms of action, applicable pediatric population, dosing, outcome data, and adverse effects of current and future treatments beyond standard therapy in severe pediatric asthma References:               Perry, R., Braileanu, G., Palmer, T. et al. The Economic Burden of Pediatric Asthma in the United States: Literature Review of Current Evidence. PharmacoEconomics 37, 155–167 (2019). Yao T, Wang J, Chang S, et al. Association of Oral Corticosteroid Bursts With Severe Adverse Events in Children. JAMA Pediatr. Published online April 19, 2021. Katial RK, Bensch GW, Busse WW, Chipps BE, Denson JL, Gerber AN, et al. Changing paradigms in the treatment of severe asthma: the role of biologic therapies. J Allergy Clin Immunol Pract 2017;5:S1–S14. Licari, A., Manti, S., Castagnoli, R. et al. Targeted Therapy for Severe Asthma in Children and Adolescents: Current and Future Perspectives. Pediatr Drugs 21, 215–237 (2019)

Episode 2:       Severe pediatric asthma-evaluation of the child, diagnostic testing, assessing steroid side effects   Description: Though severe pediatric asthma only represents from 2 to 5% of the children suffering with this condition, it represents a major share of the cost, resource utilization, and morbidity. It is important that allergists have a good gasp of this condition and how it differs from the adult population. Topics include appropriate workup, comorbidities, steroid burden.   Learning Objectives: Be able to discuss the burden of severe pediatric asthma and issues in optimal medication adherence in this population Be able to evaluate the child with severe asthma and screen for corticosteroid overuse in and remedies to decrease it in this population Be able to interpret the mechanisms of action, applicable pediatric population, dosing, outcome data, and adverse effects of current and future treatments beyond standard therapy in severe pediatric asthma References:               Perry, R., Braileanu, G., Palmer, T. et al. The Economic Burden of Pediatric Asthma in the United States: Literature Review of Current Evidence. PharmacoEconomics 37, 155–167 (2019). Yao T, Wang J, Chang S, et al. Association of Oral Corticosteroid Bursts With Severe Adverse Events in Children. JAMA Pediatr. Published online April 19, 2021. Katial RK, Bensch GW, Busse WW, Chipps BE, Denson JL, Gerber AN, et al. Changing paradigms in the treatment of severe asthma: the role of biologic therapies. J Allergy Clin Immunol Pract 2017;5:S1–S14. Licari, A., Manti, S., Castagnoli, R. et al. Targeted Therapy for Severe Asthma in Children and Adolescents: Current and Future Perspectives. Pediatr Drugs 21, 215–237 (2019)

Episode 1: Severe pediatric asthma-burden of disease, adherence issues, and comorbidities   Description: Though severe pediatric asthma only represents from 2 to 5% of the children suffering with this condition, it represents a major share of the cost, resource utilization, and morbidity. It is important that allergists have a good gasp of this condition and how it differs from the adult population. Topics include appropriate workup, comorbidities, steroid burden.   Learning Objectives: Be able to discuss the burden of severe pediatric asthma and issues in optimal medication adherence in this population Be able to evaluate the child with severe asthma and screen for corticosteroid overuse in and remedies to decrease it in this population Be able to interpret the mechanisms of action, applicable pediatric population, dosing, outcome data, and adverse effects of current and future treatments beyond standard therapy in severe pediatric asthma References:               Perry, R., Braileanu, G., Palmer, T. et al. The Economic Burden of Pediatric Asthma in the United States: Literature Review of Current Evidence. PharmacoEconomics 37, 155–167 (2019). Yao T, Wang J, Chang S, et al. Association of Oral Corticosteroid Bursts With Severe Adverse Events in Children. JAMA Pediatr. Published online April 19, 2021. Katial RK, Bensch GW, Busse WW, Chipps BE, Denson JL, Gerber AN, et al. Changing paradigms in the treatment of severe asthma: the role of biologic therapies. J Allergy Clin Immunol Pract 2017;5:S1–S14. Licari, A., Manti, S., Castagnoli, R. et al. Targeted Therapy for Severe Asthma in Children and Adolescents: Current and Future Perspectives. Pediatr Drugs 21, 215–237 (2019)

Episode 3 discusses access to treatment disparities for nasal polyposis in minority and underserved populations.   Today's speakers have the following disclosures: Gerald Lee, MD: Nothing to disclose Maha Mahdavinia, MD, PhD: Consulting, Fee: Optinose Anjeni Keswani, MD: Nothing to disclose   This podcast series is supported by Sanofi Regeneron.

Episode 2 discusses the impact of air pollution and the environment on CRSwNP and how this disproportionately affects minority and underserved populations.   Today's speakers have the following disclosures: Gerald Lee, MD: Nothing to disclose Maha Mahdavinia, MD, PhD: Consulting, Fee: Optinose Anjeni Keswani, MD: Nothing to disclose   This podcast series is supported by Sanofi Regeneron.

Episode 1 provides an overview of the subtypes of CRSwNP and reviews the evidence for disparities in the burden of disease on minority and underserved populations and discusses the reasons for these disparities.   Today's speakers have the following disclosures: Gerald Lee, MD: Nothing to disclose Maha Mahdavinia, MD, PhD: Consulting, Fee: Optinose Anjeni Keswani, MD: Nothing to disclose   This podcast series is supported by Sanofi Regeneron.

This episode will describe best practices for addressing disparities in care for patients with atopic dermatitis and how to implement specific health equity strategies to improve access to atopic dermatitis care and increase patient adherence to treatment. Disparities in Atopic Dermatitis Miniseries Host: Payel Gupta, MD, FACAAI Expert: Anil Nanda, MD, FACAAI Expert: Andrew Alexis, MD, MPH Expert: Marcella Aquino, MD, FACAAI The miniseries is hosted by Payel Gupta, MD,  a triple board-certified specialist and the Medical Director for Allergy, Asthma, Immunology & ENT at LifeMD.com. She is practicing in New York City and is an assistant clinical professor at SUNY Downstate Medical Center and Clinical Instructor at Mount Sinai Medical Center.  She is a volunteer national spokesperson for the American Lung Association and co-host of The Itch Podcast. Joining her are Anil Nanda, MD, who is in private community practice at the Asthma and Allergy Center in Lewisville and Flower Mound, Texas and is Clinical Associate Professor of Medicine, at the Division of Allergy and Immunology, University of Texas Southwestern Medical Center, Dallas, TX; Andrew F. Alexis, MD, MPH, who is the Vice-Chair for Diversity and Inclusion for the Department of Dermatology and Professor of Clinical Dermatology at Weill Cornell Medical College in New York City. He is the former Chair of the Department of Dermatology at Mount Sinai Morningside and Mount Sinai West. Having served as Director of the first-of-its-kind Skin of Color Center for over 15 years, his work has helped to advance patient care, research, and education pertaining to dermatologic disorders that are prevalent in populations with skin of color; and Marcella Aquino, MD, who is an Associate Professor of Pediatrics at the Warren Alpert Medical School of Brown University and staff at Rhode Island Hospital/Hasbro Children's Hospital. Her interests include allergic skin diseases particularly allergic contact dermatitis, atopic dermatitis, and drug allergy. She has presented on these topics at national meetings and published in textbooks and peer reviewed journals with a focus on contact dermatitis including patch testing, the role of contact dermatitis in atopic dermatitis patients, drug allergy challenges/desensitizations and the use of simulation for the instruction of anaphylaxis/allergic emergencies. Dr. Aquino was awarded an implementation grant by the ACAAI Foundation looking a multi-level contributing factors to racial and ethnic disparities in urban children in asthma and atopic dermatitis. This podcast series is supported by Pfizer.

This episode will describe the influence of skin color in diagnosing and managing patients with atopic dermatitis.   Disparities in Atopic Dermatitis Miniseries Host: Payel Gupta, MD, FACAAI Expert: Anil Nanda, MD, FACAAI Expert: Andrew Alexis, MD, MPH Expert: Marcella Aquino, MD, FACAAI The miniseries is hosted by Payel Gupta, MD,  a triple board-certified specialist and the Medical Director for Allergy, Asthma, Immunology & ENT at LifeMD.com. She is practicing in New York City and is an assistant clinical professor at SUNY Downstate Medical Center and Clinical Instructor at Mount Sinai Medical Center.  She is a volunteer national spokesperson for the American Lung Association and co-host of The Itch Podcast. Joining her are Anil Nanda, MD, who is in private community practice at the Asthma and Allergy Center in Lewisville and Flower Mound, Texas and is Clinical Associate Professor of Medicine, at the Division of Allergy and Immunology, University of Texas Southwestern Medical Center, Dallas, TX; Andrew F. Alexis, MD, MPH, who is the Vice-Chair for Diversity and Inclusion for the Department of Dermatology and Professor of Clinical Dermatology at Weill Cornell Medical College in New York City. He is the former Chair of the Department of Dermatology at Mount Sinai Morningside and Mount Sinai West. Having served as Director of the first-of-its-kind Skin of Color Center for over 15 years, his work has helped to advance patient care, research, and education pertaining to dermatologic disorders that are prevalent in populations with skin of color; and Marcella Aquino, MD, who is an Associate Professor of Pediatrics at the Warren Alpert Medical School of Brown University and staff at Rhode Island Hospital/Hasbro Children's Hospital. Her interests include allergic skin diseases particularly allergic contact dermatitis, atopic dermatitis, and drug allergy. She has presented on these topics at national meetings and published in textbooks and peer reviewed journals with a focus on contact dermatitis including patch testing, the role of contact dermatitis in atopic dermatitis patients, drug allergy challenges/desensitizations and the use of simulation for the instruction of anaphylaxis/allergic emergencies. Dr. Aquino was awarded an implementation grant by the ACAAI Foundation looking a multi-level contributing factors to racial and ethnic disparities in urban children in asthma and atopic dermatitis. This podcast series is supported by Pfizer.

This episode will review racial, ethnic, socioeconomic, and geographic disparities related to atopic dermatitis. Disparities in Atopic Dermatitis Miniseries Host: Payel Gupta, MD, FACAAI Expert: Anil Nanda, MD, FACAAI Expert: Andrew Alexis, MD, MPH Expert: Marcella Aquino, MD, FACAAI The miniseries is hosted by Payel Gupta, MD,  a triple board-certified specialist and the Medical Director for Allergy, Asthma, Immunology & ENT at LifeMD.com. She is practicing in New York City and is an assistant clinical professor at SUNY Downstate Medical Center and Clinical Instructor at Mount Sinai Medical Center.  She is a volunteer national spokesperson for the American Lung Association and co-host of The Itch Podcast. Joining her are Anil Nanda, MD, who is in private community practice at the Asthma and Allergy Center in Lewisville and Flower Mound, Texas and is Clinical Associate Professor of Medicine, at the Division of Allergy and Immunology, University of Texas Southwestern Medical Center, Dallas, TX; Andrew F. Alexis, MD, MPH, who is the Vice-Chair for Diversity and Inclusion for the Department of Dermatology and Professor of Clinical Dermatology at Weill Cornell Medical College in New York City. He is the former Chair of the Department of Dermatology at Mount Sinai Morningside and Mount Sinai West. Having served as Director of the first-of-its-kind Skin of Color Center for over 15 years, his work has helped to advance patient care, research, and education pertaining to dermatologic disorders that are prevalent in populations with skin of color; and Marcella Aquino, MD, who is an Associate Professor of Pediatrics at the Warren Alpert Medical School of Brown University and staff at Rhode Island Hospital/Hasbro Children's Hospital. Her interests include allergic skin diseases particularly allergic contact dermatitis, atopic dermatitis, and drug allergy. She has presented on these topics at national meetings and published in textbooks and peer reviewed journals with a focus on contact dermatitis including patch testing, the role of contact dermatitis in atopic dermatitis patients, drug allergy challenges/desensitizations and the use of simulation for the instruction of anaphylaxis/allergic emergencies. Dr. Aquino was awarded an implementation grant by the ACAAI Foundation looking a multi-level contributing factors to racial and ethnic disparities in urban children in asthma and atopic dermatitis. This podcast series is supported by Pfizer.  

For today's episode we will be reviewing articles from the May-June 2021 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch Please watch out for continued discussion on this topic in the ACAAI Community on DocMatter, we'll have key talk takeaways and an engaging question with the opportunity for ongoing conversation about today's topic! Article Links:  A Behavior Change Intervention Aimed at Increasing Physical Activity Improves Clinical Control in Adults With Asthma: A Randomized Controlled Trial.   The Predicative Clinical Features Associated with Chronic Cough That Has a Single Underlying Cause.    Trends in US hospitalizations for anaphylaxis among infants and toddlers: 2006 to 2015.

For today's episode we will be reviewing articles from the January-February 2021 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch Please watch out for continued discussion on this topic in the ACAAI Community on DocMatter, we'll have key talk takeaways and an engaging question with the opportunity for ongoing conversation about today's topic! Article Links: Early life acetaminophen exposure, glutathione S-transferase genes, and development of adolescent asthma in a high-risk birth cohort.   Health Services Utilization Is Increased in Poor Perceivers of Bronchoconstriction and Hyperinflation in Asthma.   Milk allergy most burdensome in multi-food allergic children.  

This episode will outline barriers to immune globulin and transplantation and offer solutions

This episode will outline each barrier discussed in podcast #1 and then offer resources and solutions

This episode will review the current evidence of underdiagnosis of PIDD in minority/underserved populations. Episode may include interview clips from a patient on how they/their children received the diagnosis of PIDD and what barriers they experienced in receiving the diagnosis of PIDD and what barriers they experienced in receiving the diagnosis of PIDD.

For today's episode we will be reviewing articles from the January-February 2021 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch Please watch out for continued discussion on this topic in the ACAAI Community on DocMatter, we'll have key talk takeaways and an engaging question with the opportunity for ongoing conversation about today's topic! Article Links: Randomized controlled trial of triple versus dual inhaler therapy on small airways in smoking asthmatics. Suboptimal treatment response to anti-IL-5 monoclonal antibodies in severe eosinophilic asthmatics with airway autoimmune phenomena. Induction of sustained unresponsiveness after egg oral immunotherapy compared to baked egg therapy in children with egg allergy. Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today's speakers have the following disclosures: Dr. Lee has nothing to disclose Dr. Kalangara Speaker and Consultant: GlaxoSmithKline Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst

For today's episode we will be reviewing articles from the November-December 2020 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch Please watch out for continued discussion on this topic in the ACAAI Community on DocMatter, we'll have key talk takeaways and an engaging question with the opportunity for ongoing conversation about today's topic! Article Links: Type 2 inflammation in chronic rhinosinusitis without nasal polyps: Another relevant endotype. Novel airway smooth muscle-mast cell interactions and a role for the TRPV4-ATP axis in non-atopic asthma. Immunoglobulin G and immunoglobulin G subclass concentrations differ according to sex and race.   Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today's speakers have the following disclosures: Dr. Lee has nothing to disclose Dr. Kalangara Speaker and Consultant: GlaxoSmithKline Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst

For today's episode we will be reviewing articles from the November-December 2020 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch Please watch out for continued discussion on this topic in the ACAAI Community on DocMatter, we'll have key talk takeaways and an engaging question with the opportunity for ongoing conversation about today's topic! Article Links: Understanding the asthmatic response to an experimental rhinovirus infection: Exploring the effects of blocking IgE.  Performance Characteristics of Spirometry With Negative Bronchodilator Response and Methacholine Challenge Testing and Implications for Asthma Diagnosis. Real-World Effectiveness and the Characteristics of a "Super-Responder" to Mepolizumab in Severe Eosinophilic Asthma.    Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today's speakers have the following disclosures: Dr. Lee has nothing to disclose Dr. Kalangara Speaker and Consultant: GlaxoSmithKline Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst

For today's episode we will be reviewing three articles from the Sept-Oct 2020 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch Please watch out for continued discussion on this topic in the ACAAI Community on DocMatter, we'll have key talk takeaways and an engaging discussion with the opportunity for ongoing conversation about today's topic! Article links: Using fractional exhaled nitric oxide to guide step-down treatment decisions in patients with asthma: a systematic review and individual patient data meta-analysis.  Omalizumab for Aspirin Hypersensitivity and Leukotriene Overproduction in Aspirin-exacerbated Respiratory Disease. A Randomized Controlled Trial. Assessing the unified airway hypothesis in children via transcriptional profiling of the airway epithelium.   Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today's speakers have the following disclosures: Drs. Lee and Kalangara has nothing to disclose Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.

For today's episode we will be reviewing three articles from the Sept-Oct 2020 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch Please watch out for continued discussion on this topic in the ACAAI Community on DocMatter, we'll have key talk takeaways with the opportunity for ongoing conversation about today's topic! Article links: Changes in asthma severity in the first year of school and difficulty learning to read. IL-5Rα marks nasal polyp IgG4- and IgE-expressing cells in aspirin-exacerbated respiratory disease.   Sialylation of immunoglobulin E is a determinant of allergic pathogenicity.   Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today's speakers have the following disclosures: Drs. Lee and Kalangara has nothing to disclose Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.

For today's episode we will be reviewing three articles from the July-August 2020 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch Please watch out for continued discussion on this topic in the ACAAI Community on DocMatter, we'll have key takeaways with the opportunity for ongoing conversation about today's topic! Article links: Reintroduction failure after negative food challenges in adults is common and mainly due to atypical symptoms.   Acute emotional stress proposed as a risk factor for anaphylaxis in patients receiving allergen immunotherapy.   Home self-monitoring in patients with asthma using a mobile spirometry system.   Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today's speakers have the following disclosures: Drs. Lee and Kalangara has nothing to disclose Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.

Show notes for Episode 16:   For today's episode we will be reviewing three articles from the July-August 2020 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch Please watch out for continued discussion on this topic in the ACAAI Community on DocMatter, we'll have key takeaways with the opportunity for ongoing conversation about today's topic! Article links: Prevalence and impact of comorbid laryngeal dysfunction in asthma: A systematic review and meta-analysis.   Trends and Disparities in Asthma Biologic Use in the United States.   Treatment Effect of Omalizumab on Severe Pediatric Atopic Dermatitis: The ADAPT Randomized Clinical Trial.   Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today's speakers have the following disclosures: Drs. Lee and Kalangara has nothing to disclose Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.

For today's episode we will be reviewing three more articles from the May-June 2020 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch Please watch out for continued discussion on this topic in the ACAAI Community on DocMatter, we'll have key talk takeaways and an engaging question with the opportunity for ongoing conversation about today's topic! Article links: Prenatal and Early-Life Exposure to Indoor Air-Polluting Factors and Allergic Sensitization at 2 Years of Age Impact of Sinus Surgery on Type 2 Airway and Systemic Inflammation in Asthma   Long-term Sublingual Immunotherapy for Peanut Allergy in Children: Clinical and Immunologic Evidence of Desensitization   Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today's speakers have the following disclosures: Drs. Lee and Kalangara has nothing to disclose Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.

For today's episode we will be reviewing three articles from the May-June 2020 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch Please watch out for continued discussion on this topic in the ACAAI Community on DocMatter, we'll have key talk takeaways and an engaging question with the opportunity for ongoing conversation about today's topic! Article links: Earlier Ingestion of Peanut After Changes to Infant Feeding Guidelines: The EarlyNuts Study   Effect of Sleep Deprivation and Exercise on Reaction Threshold in Adults With Peanut Allergy: A Randomized Controlled Study   Treatment With a Platelet-Activating Factor Receptor Antagonist Improves Hemodynamics and Reduces Epinephrine Requirements, in a Lethal Rodent Model of Anaphylactic Shock   Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today's speakers have the following disclosures: Drs. Lee and Kalangara has nothing to disclose Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.

Today we have a special episode of AllergyTalk! Based on your feedback, we will be discussing the approach to delayed reactions to medications, a challenging dilemma in allergy and immunology! If you have an idea for a future episode of AllergyTalk, email us at allergytalk@acaai.org!   The ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Disclosures: Drs. Lee and Kalangara have nothing to disclose. Dr. Khan receives royalties from a book on drug allergy testing published by Elsevier.

Today we have a special episode of AllergyTalk! Based on your feedback, we will be discussing the approach to delayed reactions to medications, a challenging dilemma in allergy and immunology! If you have an idea for a future episode of AllergyTalk, email us at allergytalk@acaai.org!   The ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Disclosures: Drs. Lee and Kalangara have nothing to disclose. Dr. Khan receives royalties from a book on drug allergy testing published by Elsevier.

For today's episode we will be reviewing three more articles from the Jan-Feb 2020 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit, head over to https://college.acaai.org/allergytalk Article Links: The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma. Altered Viscosity of Nasal Secretions in Postnasal Drip. Walnut antigens can trigger autoantibody development in patients with pemphigus vulgaris through a "hit-and-run" mechanism. Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today's speakers have the following disclosures: Drs. Lee and Kalangara have nothing to disclose. Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.

For today's episode we will be reviewing three articles from the Jan-Feb 2020 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit, head over to https://college.acaai.org/allergytalk Article links: Loss of bronchoprotection with ICS plus LABA treatment, β-receptor dynamics, and the effect of alendronate. Step-Up Therapy in Black Children and Adults with Poorly Controlled Asthma. Unexpected and unintended cure of habit cough by proxy. Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today's speakers have the following disclosures: Drs. Lee and Kalangara have nothing to disclose. Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.

In the third of three podcasts focusing on Cough, host Dr. Purvi Parikh joins with Dr. Kevin Murphy and Dr. Mandel Sher to look at the what does and doesn't work in treating cough. They review the current therapies and what new therapies options are coming in the future. This podcast is supported by an educational grant from Merck & Co., Inc. ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today's speakers have the following disclosures: Kevin Murphy, MD Honoraria: AstraZeneca, Genentech, Novartis, Sanofi, Regeneron Purvi Parikh, MD Honoraria: AstraZeneca, Takeda, Genentech/Novartis, Aimmune; Contracted research: AstraZeneca Mandel Sher, MD Advisory Committee, Consulting Fee: Merck; Speaker, Honorarium: Optinose; Consulting, Fee: NeRRe; Clinical Investigator, Contracted Research: Attenua, Merck, NeRRe  

In this, the second of three podcasts focusing on Cough, host Dr. Purvi Parikh discusses diagnosing cough with Dr. Mandel Sher and Dr. Kevin Murphy. They address diagnosing chronic cough in children and adults. Protracted bacterial bronchitis, the role of GERD in cough, and habit cough are also discussed. This podcast is supported by an educational grant from Merck & Co., Inc. ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today's speakers have the following disclosures: Kevin Murphy, MD Honoraria: AstraZeneca, Genentech, Novartis, Sanofi, Regeneron Purvi Parikh, MD Honoraria: AstraZeneca, Takeda, Genentech/Novartis, Aimmune; Contracted research: AstraZeneca Mandel Sher, MD Advisory Committee, Consulting Fee: Merck; Speaker, Honorarium: Optinose; Consulting, Fee: NeRRe; Clinical Investigator, Contracted Research: Attenua, Merck, NeRRe

In this, the first of three podcasts focusing on Cough, host Dr. Purvi Parikh speaks with Dr. Mandel Sher and Dr. Kevin Murphy about the “true” cough reflex, the cough response, and cough hypersensitivity. This podcast is supported by an educational grant from Merck & Co., Inc. ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today's speakers have the following disclosures: Kevin Murphy, MD Honoraria: AstraZeneca, Genentech, Novartis, Sanofi, Regeneron Purvi Parikh, MD Honoraria: AstraZeneca, Takeda, Genentech/Novartis, Aimmune; Contracted research: AstraZeneca Mandel Sher, MD Advisory Committee, Consulting Fee: Merck; Speaker, Honorarium: Optinose; Consulting, Fee: NeRRe; Clinical Investigator, Contracted Research: Attenua, Merck, NeRRe

For this episode, we will be reviewing three articles from the Nov-Dec 2019 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. To subscribe to Allergy Watch, head over to https://college.acaai.org/publications/allergywatch We're pleased to introduce CME credit for Allergy Watch episodes of AllergyTalk! For details, head on over to the AllergyTalk webpage at https://college.acaai.org/allergytalk Article Links: Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety. Paired acute-baseline serum tryptase levels in perioperative anaphylaxis: An observational study. Immunization of cats to induce neutralizing antibodies against Fel d 1, the major feline allergen in human subjects. Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today's speakers have the following disclosures: Drs. Lee and Kalangara have nothing to disclose. Dr. Fineman: Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.

For this episode, we will be reviewing three articles about asthma from the Nov-Dec 2019 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. To subscribe to Allergy Watch, head over to https://college.acaai.org/publications/allergywatch We're pleased to introduce CME credit for Allergy Watch episodes of AllergyTalk! For details, head on over to the AllergyTalk webpage at https://college.acaai.org/allergytalk Article Links: Racial disparities in asthma-related health care use in the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. Omega-3 and Omega-6 Intake Modifies Asthma Severity and Response to Indoor Air Pollution in Children.  Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma.  Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today's speakers have the following disclosures: Drs. Lee and Kalangara have nothing to disclose. Dr. Fineman: Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.

Welcome to Episode 8, part 2 of Allergy Talk! I sat down with my co-host Stan Fineman, MD, MBA, ACAAI to review the practice management resources from the ACAAI! If you have a topic you'd like to cover in a future podcast, let us know at allergytalk@acaai.org. ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today's speakers have the following disclosures: Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron. Dr. Lee has no relevant disclosures.

Welcome to Episode 8 of Allergy Talk, a roundup of the latest in the field of Allergy and Immunology by the American College of Allergy, Asthma, and Immunology! At the 2019 ACAAI Annual Meeting in Houston, Texas we interviewed the leaders of the College on how the ACAAI helps its members and what to expect for 2020! If you have a topic you'd like to cover in a future podcast, let us know at allergytalk@acaai.org. ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today's speakers have the following disclosures: Dr. Mahr:  Research / Consultant / Advisory Board / Speaker / Honorarium: Aimmune, ALK, AZ, Boeringer-Ingelheim, Kaleo, GSK,  Optinose, Sanofi-Genzyme - Regeneron Dr. Meadows: Speaker: Regeneron, Pfizer, AZ, GSK, Optinose Consultant: Aimmune Dr. Lee: No relevant disclosures

We are excited to present a special 2 part episode of Allergytalk! Dr. Brian Vickery, the principal investigator of the PALISADE study that led to the first FDA-approved peanut immunotherapy, joins us to discuss his personal story and his thoughts on the future of food immunotherapy! If you have a topic you'd like to cover in a future podcast, let us know at allergytalk@acaai.org

We are excited to present a special 2 part episode of Allergytalk! Dr. Brian Vickery, the principal investigator of the PALISADE study that led to the first FDA-approved peanut immunotherapy, joins us to discuss his personal story and his thoughts on the future of food immunotherapy! If you have a topic you'd like to cover in a future podcast, let us know at allergytalk@acaai.org.  

We are excited to present a special episode of Allergytalk! Dr. Jennifer Shih, MD joins the podcast to discuss the use of telemedicine in allergy/immunology!   Please give us feedback, corrections, and suggestions! If you have a topic you'd like to cover in a future podcast, let us know at  allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today's speakers have the following disclosures: Dr. Lee was on an advisory board for Teva. Dr. Kalangara has received consulting fees from AstraZeneca. Dr. Shih was on advisory board for Teva and Tekeda.

This is part 2 of our summaries from the July-August 2019 issue of Allergy Watch: Investigation of the factors that determine the severity of allergic reactions to Hymenoptera venoms https://www.ncbi.nlm.nih.gov/pubmed/30819281 New-Onset Asthma in Adults: What Does the Trigger History Tell Us? https://www.ncbi.nlm.nih.gov/pubmed/30240884 Age-Specific Associations of Ozone and Fine Particulate Matter with Respiratory Emergency Department Visits in the United States https://www.ncbi.nlm.nih.gov/pubmed/30277796 Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today's speakers have the following disclosures: Dr. Lee was on an advisory board for Teva. Dr. Kalangara has received consulting fees from AstraZeneca. Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.

For today's episode we will be reviewing three articles from the July-August 2019 issue of Allergy Watch: Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis https://www.ncbi.nlm.nih.gov/pubmed/30488542 Allergen content in German cockroach extracts and sensitization profiles to a new expanded set of cockroach allergens determine in vitro extract potency for IgE reactivity https://www.ncbi.nlm.nih.gov/pubmed/30170124 New IgE immediate hypersensitivity reactions on reintroduction of food restricted for treatment of eosinophilic esophagitis https://www.ncbi.nlm.nih.gov/pubmed/30684739 Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today's speakers have the following disclosures: Dr. Lee was on an advisory board for Teva. Dr. Kalangara has received consulting fees from AstraZeneca. Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.

For today's episode we will be reviewing three articles about food allergy and eczema from the May-June 2019 issue of Allergy Watch: The Basophil Activation Test reduces the need for a food challenge test in children suspected of IgE-mediated cow's milk allergy. https://www.ncbi.nlm.nih.gov/pubmed/30408255 Oral food challenge failures among foods restricted because of atopic dermatitis. https://www.ncbi.nlm.nih.gov/pubmed/30326323 The nonlesional skin surface distinguishes atopic dermatitis with food allergy as a unique endotype. https://www.ncbi.nlm.nih.gov/pubmed/30787169 Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today's speakers have the following disclosures: Dr. Lee was on an advisory board for Teva. Dr. Kalangara has received consulting fees from Astra Zenica. Dr. Fineman  Speaker: AstraZenca, Boehringer Ingelheim, Shire Research: Aimmune, DBV, Shire, Regeneron.

For today's episode we will be reviewing three articles about asthma from the May-June 2019 issue of Allergy Watch: Reslizumab Compared with Benralizumab in Patients with Eosinophilic Asthma: A Systematic Literature Review and Network Meta-Analysis. https://www.ncbi.nlm.nih.gov/pubmed/30217529 Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison. https://www.ncbi.nlm.nih.gov/pubmed/30205189 Indirect Treatment Comparisons and Biologics https://www.ncbi.nlm.nih.gov/pubmed/30612667 Endotypes of severe allergic asthma patients who clinically benefit from anti?IgE therapy https://www.ncbi.nlm.nih.gov/pubmed/30107059/ Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthma https://www.ncbi.nlm.nih.gov/pubmed/29301922 Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today's speakers have the following disclosures: Dr. Lee was on an advisory board for Teva. Dr. Kalangara has received consulting fees from Astra Zenica. Dr. Fineman  Speaker: AstraZenca, Boehringer Ingelheim, Shire Research: Aimmune, DBV, Shire, Regeneron.

With guest Stanley Fineman, MD, MBA, FACAAI, editor-in-chief of AllergyWatch.